Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder

Journal of Veterinary Internal Medicine

Volumn 24, Issue 5, 2010, Pages 1124-1130

  Abbo, A H ^a,d   Jones, D R ^c   Masters, A R ^c   Stewart, J C ^a   Fourez, L ^a,d   Knapp, D W ^a,b,d  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Bladder cancer; Canine species; Dog species

Indexed keywords

ANTINEOPLASTIC AGENT; MITOMYCIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLADDER TUMOR; BLOOD; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; IC 50; INTRAVESICAL DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DOG DISEASES; DOGS; FEMALE; INHIBITORY CONCENTRATION 50; MALE; MITOMYCIN; URINARY BLADDER NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 77957897981     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0569.x     Document Type: Article

References (22)

1. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med 2003;17:136-144.
2. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder: A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-59.
3. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
4. Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996;209:1588-1591.
5. Moore AS, Cardona A, Shapiro W, et al. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra: A retrospective study of 15 dogs. J Vet Intern Med 1990;4:148-152.
6. Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188.
7. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
8. Henry CJ, McCawDL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
9. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221-226.
10. Wientjes MG, Dalton JT, Badalament RA, et al. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991;51:4347-4354.
11. Nishiyama M, Suzuki K, Kumazaki T, et al. Molecular targeting of mitomycin C chemotherapy. Int J Cancer 1997;72:649-656.
12. Cummings J, Spanswich VJ, Tomasz M, et al. Enzymology of mitomycin C metabolic activation in tumor tissue: Implications for enzyme-directed bioreductive drug development. Biochem Pharmacol 1998;56:405-414.
13. Kohn H, Zein N, Lin XQ, et al. Mechanistic studies on the mode of reaction of mitomycin C under catalytic and electrochemical reductive conditions. J Am Chem Soc 1987;109:1833-1840.
14. Rooseboom M, Commandeur JN, Vermeulen NP. Enzymecatalyzed activation of anticancer prodrugs. Pharmacol Rev 2004; 56:53-102.
15. Dalton JT, Wientjes MG, Badalament RA, et al. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991;51:5144-5152.
16. Hurle R, Manzetti A, Losa A, et al. Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: Long-term results. Urol Int 1998;61:220-226.
17. Milani C, Bassi P, Meneghini A, et al. Mitomycin C in multiple superficial bladder tumors: Short-term therapy, long-term results. Urol Int 1992;48:154-156.
18. Pavlotsky A, Eidelman A, Barak F, et al. Long-term followup of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C. J Surg Oncol 1995;60:191-195.
19. Foo KT, Tan EC, Tung KH, et al. Intravesical chemotherapy for superficial carcinoma of the bladder. Singapore Med J 1991; 32:420-422.
20. Sorber M, De Bruijn EA, Kockx M, et al. Effects and systemic uptake of new mitomycin C analogue KW-2149 in Beagle dogs after intravesical administration. Urol Res 1995;23: 157-161.
21. Dhawan D, Ramos-Vara JA, Stewart JC, et al. Canine invasive transitional cell carcinoma cell lines: In vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol Oncol 2009;27:284-292.
22. VCOG. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2: 194-213.